PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

MOZ: double bogey. Mozz response is faulty on at least two...

  1. 6 Posts.
    lightbulb Created with Sketch. 9

    MOZ: double bogey.

    Mozz response is faulty on at least two points.

    Point 1: PAR is no longer “fast track”. The slow postponed FDA response clearly demonstrates this. NOT GOOD NEWS.

    Point 2: Claims of magnificent PAR generated data are not supported by any publications in leading OA journals. NOTHING but promises- promises- promises. MaRVeL oral PPS publication in British Medical Journal – open, a peer reviewed article. Is PAR data package amateur flawed and non-compliant. NOT GOOD NEWS.

    https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000654853

    https://bmjopen.bmj.com/content/bmjopen/14/5/e083046.full.pdf

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985017/

    https://www.sydney.edu.au/medicine-health/about/our-people/academic-staff/david.hunter.html


    DYOR. Just an opinion.

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.